CIK 0001662774 · Non-accelerated filer<br>Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 901024039
- Phone
- 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 70 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-12 | Lamond David Director | Purchase | +22,327 | $1.02 | $23K | 2,302,291 |
| 2023-12-07 | Lamond David Director | Purchase | +19,123 | $1.01 | $19K | 2,279,664 |
| 2023-12-06 | Lamond David Director | Purchase | +19,123 | $1.02 | $20K | 2,260,541 |
| 2023-12-05 | Lamond David Director | Purchase | +19,123 | $1.01 | $19K | 2,241,418 |
| 2023-12-01 | Lamond David Director | Purchase | +14,378 | $0.94 | $14K | 2,222,295 |
| 2023-11-30 | Lamond David Director | Purchase | +14,378 | $0.90 | $13K | 2,207,917 |
| 2023-11-29 | Lamond David Director | Purchase | +14,378 | $0.98 | $14K | 2,193,539 |
| 2023-10-24 | Hannah Brendan Chief Business Officer and COO | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2023-10-23 | Benatti Luca Director | Grant or award · Employee Stock Option (right to buy) | +54,000 | 54,000 | ||
| 2023-10-23 | Janhofer Guenter Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2023-09-01 | Ryan Charles S. President | Grant or award · Employee Stock Option (right to buy) | +545,000 | 545,000 | ||
| 2023-08-31 | Lamond David Director | Purchase | +41,026 | $1.32 | $54K | 2,179,161 |
| 2023-08-30 | Lamond David Director | Purchase | +41,026 | $1.31 | $54K | 2,138,135 |
| 2023-08-17 | Lamond David Director | Purchase | +24,766 | $1.29 | $32K | 2,097,109 |
| 2023-08-16 | Lamond David Director | Purchase | +117,348 | $1.29 | $151K | 2,072,343 |
| 2023-08-15 | Lamond David Director | Purchase | +107,886 | $1.32 | $142K | 1,954,995 |
| 2023-08-10 | Thye Dirk Chief Executive Officer | Purchase | +88,000 | $1.26 | $111K | 448,911 |
| 2023-08-08 | Thye Dirk Chief Executive Officer | Purchase | +80,000 | $1.24 | $99K | 360,911 |
| 2023-08-08 | Hannah Brendan Chief Business Officer | Purchase | +71,762 | $1.22 | $88K | 201,555 |
| 2023-08-08 | McLoughlin Margaret Director | Purchase | +8,000 | $1.23 | $10K | 8,000 |
Page 5 of 8 · 149 trades